Shandong University of Traditional Chinese Medicine.
Department of Traditional Chinese Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan.
Medicine (Baltimore). 2020 Dec 18;99(51):e23306. doi: 10.1097/MD.0000000000023306.
To analyze the effects of acupoint injection in the treatment of non-dialysis dependent chronic kidney disease through a systematic review with meta-analysis.
This systematic review with meta-analysis was conducted following the recommendations of the declaration of PRISMA. Full-text literature of randomized controlled trial of acupoint injection therapy for non-dialysis chronic kidney disease was searched in PubMed, Embase, Cochrane Library, China National Knowledge Internet, the Chinese Scientific Journal Database, the Wanfang Database, China Biology Medicine database. The efficacy and safety of acupoint injection for non-dialysis chronic kidney disease were evaluated.
Seventeen studies containing 1414 patients met the criteria. The results shows that acupoint injection combined with basic treatment can significantly improve the levels of Ccr (WMD = 4.81; 95% CI:2.54 to 7.08) and Hb (WMD = 4.56; 95% CI:1.72 to 7.39), reduce the levels of BUN (WMD = -0.90; 95% CI: -1.26 to -0.54)and Scr (WMD = -7.66; 95% CI: -12.39 to -2.93), and improve the effective rate (OR = 3.12; 95% CI: 2.29 to 4.26).
Our current analysis showed that combined acupoint injection therapy can reduce the levels of BUN and Scr, and increase Ccr and Hb in non-dialysis CKD patients. However, the existing evidence is still insufficient due to the high risk of included trial bias, and future research needs to improve methodological quality.Registration number: CRD42020168143.
通过系统评价和荟萃分析分析穴位注射治疗非透析依赖性慢性肾脏病的效果。
本系统评价和荟萃分析按照 PRISMA 宣言的建议进行。在 PubMed、Embase、Cochrane 图书馆、中国国家知识网、中国科学期刊数据库、万方数据库、中国生物医学数据库中检索穴位注射治疗非透析慢性肾脏病的随机对照试验的全文文献。评价穴位注射治疗非透析慢性肾脏病的疗效和安全性。
符合标准的研究共 17 项,包含 1414 例患者。结果表明,穴位注射联合基础治疗可显著提高 Ccr(WMD=4.81;95%CI:2.54 至 7.08)和 Hb(WMD=4.56;95%CI:1.72 至 7.39)水平,降低 BUN(WMD=-0.90;95%CI:-1.26 至-0.54)和 Scr(WMD=-7.66;95%CI:-12.39 至-2.93)水平,提高有效率(OR=3.12;95%CI:2.29 至 4.26)。
我们目前的分析表明,联合穴位注射疗法可降低非透析性 CKD 患者的 BUN 和 Scr 水平,增加 Ccr 和 Hb。然而,由于纳入试验的偏倚风险较高,现有证据仍然不足,未来的研究需要提高方法学质量。注册号:CRD42020168143。